Chester County News and Community Website
RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) announced that it recently filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administration (FDA) focused on patients …
NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI Read More
PHILADELPHIA, PA — Amicus Therapeutics (Nasdaq: FOLD) announced that the U.S. Food and Drug Administration (FDA) this week accepted for review the Biologics License Application (BLA) for cipaglucosidase alfa and …
FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease Read More
NEWTOWN, PA — Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in …
Onconova Announces Data Supporting Anti-Cancer Activity of Rigosertib-Nivolumab Combination Read More
PHILADELPHIA, PA — Virion Therapeutics, LLC announced M. Michelle Berrey, M.D., M.P.H. and Williamson “Bill” Bradford, M.D., Ph.D. have joined the Company’s Board of Directors. In addition, Dr. Teresa Wright …
Virion Therapeutics Announces New Board Members Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of …
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy Read More
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with …
Idera Pharmaceuticals Announces Corporate Updates Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic …
FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory …
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab Read More
WASHINGTON. D.C. — U.S. Department of Veterans Affairs (VA) researchers and Veteran volunteers from the Atlanta and San Antonio VA medical centers were part of a recently published study that yielded crucial …
VA Plays Crucial Role in COVID-19 Treatment Study Read More